CERS Shariah Compliance
Screening Methodology: AAOIFI
LOCKED
Cerus Corp. Stock Analysis CERS
United States Health Care Micro Cap Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 281 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Read More CERS Chart
Cerus Corp vs S&P 500 Comparative Returns
Analysis of CERS stock performance compared to the broader market (S&P 500) across multiple timeframes.
YTD Performance
- Cerus Corp (CERS) -11.69%
- S&P 500 -4.27%
Cerus Corp Underperformed S&P 500 by 7.42%
1Y Performance
- Cerus Corp (CERS) -27.66%
- S&P 500 8.86%
Cerus Corp Underperformed S&P 500 by 36.52%
3Y Performance
- Cerus Corp (CERS) -72.53%
- S&P 500 37.21%
Cerus Corp Underperformed S&P 500 by 109.74%
5Y Performance
- Cerus Corp (CERS) -75.14%
- S&P 500 92.3%
Cerus Corp Underperformed S&P 500 by 167.44%
Key Statistics
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.35Volume
1.16MP/E Ratio (TTM)
-52 Week Range
Market Cap
289.83MAvg. Volume
1.13MDividend Yield
-Financial Metrics & Statements
- Per Share Data
- Ratios
- Statements
| Currency: USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Revenue per Share (TTM) | 0.68 | 0.92 | 1.06 | 1.03 | - |
EBIT per Share (TTM) | -0.35 | -0.28 | -0.19 | -0.15 | - |
Earnings per Share (EPS) (TTM) | - | - | -0.24 | - | - |
EPS Forward | - | -0.32 | -0.24 | -0.21 | - |
Super Investors
Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.
Community-Curated Collections ( With CERS )
View AllCommunity-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.
FAQ's
Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.
Alternate Halal Stocks
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
